GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (LTS:0RPD) » Definitions » Beneish M-Score

Vifor Pharma AG (LTS:0RPD) Beneish M-Score : -3.04 (As of Apr. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Vifor Pharma AG Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.04 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Vifor Pharma AG's Beneish M-Score or its related term are showing as below:

LTS:0RPD' s Beneish M-Score Range Over the Past 10 Years
Min: -3.33   Med: -2.47   Max: -1.42
Current: -3.04

During the past 13 years, the highest Beneish M-Score of Vifor Pharma AG was -1.42. The lowest was -3.33. And the median was -2.47.


Vifor Pharma AG Beneish M-Score Historical Data

The historical data trend for Vifor Pharma AG's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vifor Pharma AG Beneish M-Score Chart

Vifor Pharma AG Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.38 -2.40 -2.88 -2.42 -3.04

Vifor Pharma AG Semi-Annual Data
Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.88 - -2.42 - -3.04

Competitive Comparison of Vifor Pharma AG's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Vifor Pharma AG's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vifor Pharma AG's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vifor Pharma AG's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Vifor Pharma AG's Beneish M-Score falls into.



Vifor Pharma AG Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Vifor Pharma AG for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8987+0.528 * 0.9668+0.404 * 0.9396+0.892 * 1.0126+0.115 * 0.7678
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.96+4.679 * -0.075104-0.327 * 0.979
=-2.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec21) TTM:Last Year (Dec20) TTM:
Total Receivables was CHF374 Mil.
Revenue was CHF1,825 Mil.
Gross Profit was CHF1,153 Mil.
Total Current Assets was CHF1,879 Mil.
Total Assets was CHF5,100 Mil.
Property, Plant and Equipment(Net PPE) was CHF187 Mil.
Depreciation, Depletion and Amortization(DDA) was CHF320 Mil.
Selling, General, & Admin. Expense(SGA) was CHF544 Mil.
Total Current Liabilities was CHF981 Mil.
Long-Term Debt & Capital Lease Obligation was CHF110 Mil.
Net Income was CHF144 Mil.
Gross Profit was CHF0 Mil.
Cash Flow from Operations was CHF527 Mil.
Total Receivables was CHF411 Mil.
Revenue was CHF1,802 Mil.
Gross Profit was CHF1,101 Mil.
Total Current Assets was CHF1,609 Mil.
Total Assets was CHF5,212 Mil.
Property, Plant and Equipment(Net PPE) was CHF302 Mil.
Depreciation, Depletion and Amortization(DDA) was CHF284 Mil.
Selling, General, & Admin. Expense(SGA) was CHF560 Mil.
Total Current Liabilities was CHF544 Mil.
Long-Term Debt & Capital Lease Obligation was CHF595 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(374.2 / 1824.6) / (411.2 / 1801.9)
=0.205086 / 0.228204
=0.8987

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1100.7 / 1801.9) / (1152.8 / 1824.6)
=0.610855 / 0.63181
=0.9668

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1878.6 + 186.8) / 5099.6) / (1 - (1609 + 302.3) / 5211.7)
=0.594988 / 0.633267
=0.9396

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1824.6 / 1801.9
=1.0126

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(284.4 / (284.4 + 302.3)) / (319.9 / (319.9 + 186.8))
=0.484745 / 0.63134
=0.7678

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(543.9 / 1824.6) / (559.5 / 1801.9)
=0.298093 / 0.310506
=0.96

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((110.1 + 981.3) / 5099.6) / ((595.3 + 544) / 5211.7)
=0.214017 / 0.218604
=0.979

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(144.4 - 0 - 527.4) / 5099.6
=-0.075104

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Vifor Pharma AG has a M-score of -2.97 suggests that the company is unlikely to be a manipulator.


Vifor Pharma AG Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Vifor Pharma AG's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Vifor Pharma AG (LTS:0RPD) Business Description

Traded in Other Exchanges
N/A
Address
Rechenstrasse 37, Saint Gallen, CHE, 9014
Vifor Pharma AG is a specialty drug manufacturing and licensing company. It researches, develops, and produces its pharmaceutical products and markets and distributes them worldwide. Most of its sales are generated in the USA, with Europe also a strong contributor. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Vifor Pharma AG (LTS:0RPD) Headlines

No Headlines